Research programme: muscle loss therapeutics - Acceleron Pharma

Drug Profile

Research programme: muscle loss therapeutics - Acceleron Pharma

Alternative Names: ACE-08X; ACE-2494; ACE-3891

Latest Information Update: 04 Mar 2016

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Class Proteins
  • Mechanism of Action TGF-beta superfamily protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Musculoskeletal disorders

Most Recent Events

  • 01 Mar 2017 Acceleron plans a phase I trial for ACE 2494 for Musculoskeletal disorders (In volunteers)
  • 25 Feb 2016 Acceleron Pharma plans to file an IND application with the US FDA in USA for Musculoskeletal disorders
  • 23 Oct 2015 Acceleron Pharma plans a phase I trial for Musculoskeletal disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top